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of-use#LAAEstimates for 2012 reveal thyroid cancer 
as the fifth most expected malignancy in 
American women. Although thyroid can-
cer is not infrequently diagnosed, it rarely 
bests its host. We understand a great deal 
about well-differentiated thyroid cancers, 
including carcinomas of the thyrocyte 
and parafollicular c-cells. We have iden-
tified a number of mutations and gene 
rearrangements responsible for familial 
and sporadic tumors. We have postulated 
about mechanisms of spread and are able 
to predict biological behaviors of par-
ticular cancer types. However, gray zones 
remain, and as physicians and scientists, 
we are never comfortable with these gray 
zones, as they potentially contain magical 
epitopes for disease eradication and serve 
as pesky reminders that medicine is not 
an exact science. In thyroid cancer, poorly 
differentiated thyroid carcinomas (PDTC) 
represent the bridge between more well 
differentiated malignancies of thyrocytes 
and the undifferentiated (anaplastic) thy-
roid carcinomas. Six years ago in Turin, a 
group of expert surgical pathologists set the 
stage for refining the diagnosis of PDTC, 
as introduced by the WHO in 2004, rather 
than it serving as a diagnosis for those enti-
ties which had “high grade features” but did 
not fit neatly into one of the other defined 
categories. The conundrum that now exists 
is the incubation period between the birth 
of this now well-defined category of thy-
roid malignancy and the application of the 
diagnostic criteria, outcomes going forward, 
and how this diagnosis becomes translated 
into action by clinicians treating the entity.
World HealtH organization 
ClassifiCation of endoCrine 
tumors, 2004
The WHO blue books are the gold stand-
ard for diagnostics in surgical pathol-
ogy. Although the literature churns out 
an abundance of new data and potential 
classification schemes, these publications 
of the WHO are the cornerstones of ana-
tomic pathology-driven diagnostics until 
they are subsequently updated by desig-
nated subspecialist pathologists of the next 
edition. The most recent classification of 
endocrine tumors was published in 2004, 
in which poorly differentiated thyroid 
carcinomas are introduced as a diagnos-
tic entity (Sobrinho-Simões et al., 2004). 
PDTC are defined as “follicular neoplasms 
that show limited evidence of structural 
follicular cell differentiation and occupy 
both morphologically and behaviorally 
an intermediate position between differ-
entiated (follicular and papillary carci-
nomas) and undifferentiated (anaplastic) 
carcinomas.” This classification has been 
intended to combine various definitions 
of PDTC that have been circulating in the 
literature and diagnostic surgical pathol-
ogy reports for many years with many 
overlapping features but varying degrees 
of broad interpretation (Sakamoto et al., 
1983; Carcangiu et al., 1984; Akslen and 
LiVolsi, 2000; Sobrinho-Simões et al., 2002; 
Hiltzik et al., 2006).
turin, 2006
About 6 years ago, a group of expert thyroid 
surgical pathologists gathered in Turin, 
Italy, to finally hash out what would be 
considered by consensus to be reproduc-
ible criteria for the diagnosis of poorly 
differentiated thyroid carcinoma (Volante 
et al., 2007). The analyzed cohort consisted 
of 83 cases assembled from Europe (Italy), 
Japan, and the United States with a rep-
resentative panel consisting of 12 thyroid 
pathologists. After a lively consensus, the 
published paper reported a   diagnostic 
scheme,  represented by the unshaded areas 
in Figure 1 (Volante et al., 2007). As part 
of the diagnostic algorithm, the tumor 
would first need to be deemed malignant. 
The growth patterns were those previously 
associated with PDTC, including solid, 
trabecular, or insular (STI) growth. The 
insular growth pattern is most familiar to 
pathologists and non-pathologists, with 
insular carcinoma often thought of as a 
high grade carcinoma with extensive necro-
sis, increased mitoses, broad infiltration of 
the surrounding thyroid tissue and beyond 
with a poor prognosis (Carcangiu et al., 
1984). Solid and trabecular growth are 
also quite familiar to surgical pathologists, 
and these two patterns have diverse con-
text. Most solid-patterned thyroid lesions 
represent follicular adenomas or benign, 
unencapsulated adenomatous nodules, but 
they may also represent solid-type papillary 
carcinoma, follicular carcinoma, or PDTC. 
Trabecular growth is largely seen in adeno-
mas, and there is a well-known malignant 
mimic, the hyalinizing trabecular tumor, 
which is usually small (<1 cm), with a fin-
gerprint-like appearance that may contain 
frequent intranuclear pseudoinclusions 
with low biological potential (Thompson, 
2011). However, less frequently, trabecular 
growth, especially in large, cellular lesions, 
is ominous appearing, and may raise the 
possibility of a more biologically aggres-
sive lesion.
The Turin criteria for the diagnosis 
of PDTC are an easy to follow flow chart 
(Figure 1, unshaded), which arrive at a 
diagnosis following a series of exclusions. 
The presence of STI growth is essential, and 
without this pattern, the tumor is immedi-
ately excluded from representing PDTC. If 
STI growth is present, but the tumor shows 
largely typical nuclear features of papillary 
thyroid carcinoma (PTC), the tumor is 
excluded. If no features of PTC are identi-
fied, the tumor is assessed for the presence 
of any of each of mitoses (≥3 mitoses per 
10 hpf), convoluted nuclei, or necrosis. Any 
or all of these features is then sufficient for 
a diagnosis of PDTC. If not, the lesion is 
deemed to be a well-differentiated follicular 
thyroid carcinoma.
These criteria appear simple. However, 
the first criterion present on the flow chart 
is that the lesion is a “malignant thyroid 
tumor of follicular cells.” Of note, encapsu-
lation is not a part of the diagnostic scheme. 
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doi: 10.3389/fendo.2012.000772009) and though reported or discussed 
in other cohorts of PDTC (Malaguarnera 
et al., 2007; Nambiar et al., 2011), it has 
not been well-studied in a significant post-
Turin cohort. Some estimates have placed 
mutations here at about 20–30% (Nikiforov 
and Nikiforova, 2011), but most of the large 
TP53 mutational studies were performed in 
the early to mid-1990s (Donghi et al., 1993; 
Fagin et al., 1993; Dobashi et al., 1994). In 
an additional large study with collaborating 
authors from the aforementioned group, 
this cohort validated the Turin criteria in a 
retrospective fashion using cases from the 
United States and Italy, showing the addi-
tion of one molecular/immunohistochemi-
cal marker, IMP3, to be an indicator of poor 
prognosis in PDTC (Asioli et al., 2010). 
The study also reiterated NRAS to be most 
commonly mutated in PDTC, including the 
prior study (about 20% of cases).
speCifiCity of diagnosis in pdtC
Ultimately, the recent reclassification of 
PDTC is intended to improve patient 
care, with more uniform, accurate report-
ing. Importantly, the criteria exist to link 
objective findings with clinical outcomes, 
biological potential, and hopefully, follow-
ing additional study, molecular mechanisms 
with targeted treatment modalities and 
improved outcomes. For instance, onco-
cytic neoplasms were excluded in the Turin 
proposal. However, in a recent validation 
by the Mayo group in collaboration with 
the Turin group, about 1/3 of tumors had 
oncocytic features (Asioli et al., 2010). Also, 
a very recent study reviewing a large cohort 
of aggressive thyroid carcinomas (129 with 
known recurrence or death) identified 18 
oncocytic PDTC (Dettmer et al., 2012). 
However, this group does not distinguish 
the 18 oncocytic PDTC from other onco-
cytic (Hürthle cell) carcinomas present 
among the 129 cases, and the majority 
(16/18) of these cases were included due to 
necrosis, in addition to STI growth pattern. 
What constitutes convoluted nuclei in this 
group (18/18), with oncocytic nuclei gener-
ally thought of as round with prominent, 
centrally located nucleoli, is unclear.
missing link
Well-differentiated thyroid carcinomas of 
follicular origin, including PTCs and fol-
licular thyroid carcinomas, have several 
known mutations or translocation events. 
(Figure 1, shaded; Rivera et al., 2010a)? 
This is unclear and untested, waiting to be 
fleshed out by retrospective, prospective, 
and collective data.
state of tHe union
Incidence of thyroid carcinomas is increas-
ing, with 2012 expected to have thyroid 
carcinoma as the fifth leading cause of 
cancer in women (Siegel and Jemal, 2012). 
Improved classification will require more 
detailed information for treatment and out-
come, with PDTC portending an interme-
diate prognosis between well-differentiated 
and undifferentiated thyroid neoplasms 
(Siironen et al., 2010). Since the Turin pro-
posal, studies have emerged using these 
new criteria. In a single molecular study, 
65 cases selected by Turin criteria were 
analyzed for mutations in BRAF, N, K, and 
HRAS, as well as translocation of RET/
PTC1, 3, and PAX8/PPARγ. The majority 
of mutations (15/65) were found in RAS 
(largely  NRAS), with a single mutation 
found in BRAF (V600E). The single BRAF 
mutation was found in a PDTC associated 
with tall cell PTC (Volante et al., 2009). 
No other mutations were identified. This 
same paper looked at p53 by immunohis-
tochemistry, with expression in ∼30% of 
tumors, but accounting for less than 20% 
of tumor staining, making mutated TP53 
unlikely to be a major contributor. TP53 is 
well-known to be mutated in undifferenti-
ated (anaplastic) carcinomas (Lavra et al., 
So, even with these clear definitions of 
PDTC, there exists an additional gray zone, 
that of the encapsulated follicular tumor 
with increased mitoses or focal necrosis 
(Figure 1, shaded). Convoluted nuclei are 
well-defined by the Turin consensus, but 
convoluted nuclei alone, without the aid 
of increased mitoses or necrosis, might be 
viewed as a subjective challenge to non-
thyroid pathology experts. Additionally, 
how should pathologists interpret solitary 
lesions that meet the Turin criteria but are 
subcentimeter?
enCapsulated lesions
As mentioned, some encapsulated lesions 
involve a diagnostic gray zone, as benign 
lesions, due to size, duration, or external 
stimuli, may contain features of PDTC. 
However, depending upon the subjective 
interpretation of the tumor’s malignancy, 
there is room for broad interpretation. 
Is the tumor malignant because there is 
necrosis and mitoses? Or, is the tumor 
malignant, and therefore the presence 
of mitoses and/or necrosis appoints that 
lesion to be a PDTC? We know of encap-
sulated thyroid carcinomas, specifically, 
follicular variant of papillary carcinoma, 
that do not require capsular invasion to 
qualify as malignant. Biological poten-
tial aside, is an encapsulated lesion with 
convoluted nuclei, necrosis, or increased 
mitoses a PDTC or an atypical neo-
plasm of uncertain biological potential 
Figure 1 | Diagnosis of poorly differentiated thyroid carcinoma based upon the Turin proposal 
(unshaded). Lesions on the periphery pending inclusion criteria (shaded).
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challenges for our clinical colleagues, who 
would like to rely more and more often 
on molecular data for individualized care 
and potential targeted therapies, some of 
which have been approached with animal 
models (Nucera et al., 2010; Chakravarty 
et al., 2011), whereas some authors pro-
pose we scrap our current classification 
system entirely (Kakudo et al., 2012). Is this 
descriptive diagnosis preventing an appro-
priate accounting of disease incidence, or 
are we displaying the limits of our current 
knowledge base while additional molecular 
and proteomic data are accrued? We would 
argue for the latter.
Validation
As the Turin criteria were released 5 years 
ago (Volante et al., 2007), there have been 
a few published validation studies (Volante 
et al., 2009; Asioli et al., 2010), including a 
recent study of oncocytic PDTC (Dettmer 
et al., 2012), controversial in that onco-
cytic tumors were excluded from the Turin 
study set. The majority of the discussion 
of the new criteria for PDTC is from a 
respectable cadre of experts (Bongiovanni 
et al., 2009; Garcia-Rostan and Sobrinho-
Simões, 2010; Volante and Papotti, 2010; 
Dettmer et al., 2011; Nambiar et al., 2011; 
Tallini, 2011).
ConClusion
The past decade has seen a shift in diagno-
sis of follicular-patterned thyroid lesions, 
including high grade lesions. The publi-
cation in 2004 of the WHO blue book on 
endocrine tumors introduced poorly dif-
ferentiated thyroid carcinoma as a distinct 
diagnostic entity. This was further well-
delineated in Turin in 2006,   providing 
tangible criteria for the everyday practic-
ing pathologist to diagnose this elusive, 
boutique entity. As we continue to gather 
data, the current classification scheme will 
either be solidified or discarded, with con-
tinuing attention paid to molecular changes 
and subsets of lesions. Clinicians treating 
patients with PDTC will need to become 
familiar with the diagnostic criteria for this 
diagnosis, constructing appropriate treat-
ment modalities and follow up for these 
patients. With additional experience, the 
diagnostic model will be tested and ulti-
mately found to be clinically relevant; and 
if not, it will be discarded for something 
deemed to be more rational.
PTCs have mutations in BRAF, occasional 
RAS subtypes, and may have translocations 
of RET/PTC 1,2 (Nikiforov and Nikiforova, 
2011). Follicular carcinomas can have aber-
rations of RAS or PAX8/PPARγ (Nikiforov 
and Nikiforova, 2011). Additional excep-
tions exist, but these are certainly most com-
mon for those who work with patients with 
thyroid cancer. Undifferentiated (anaplas-
tic) thyroid carcinomas (ATC), in addition 
to possible prior BRAF or RAS mutations, 
may harbor additional mutations in TP53 
or beta-catenin (CTNNB1; Nikiforov and 
Nikiforova, 2011). This mechanism of 
transformation is thought to be a multi-
hit hypothesis, as ATC with associated 
more well-differentiated components have 
been shown to have mutations in BRAF in 
the well-differentiated component, with 
the additional CTNNB1  or  TP53 muta-
tion seen only in the undifferentiated areas 
(Nikiforov, 2004; Quiros et al., 2005).
However, this is not how we generally 
encounter these cancers. Most, seen micro-
scopically, do not have a nice transition for 
us to identify tumor origin. Additionally, 
we may discover late recurrences of well-
differentiated tumors as something more 
sinister, often after some treatment modal-
ity other than surgical excision.
Well-differentiated CarCinomas 
WitH HigH grade features
We would like to briefly discuss the concept 
of a well-differentiated carcinoma with high 
grade features. Although papillary-type 
PDTC can show concurrent cancer types, 
many cancers exist as majority PTCs with 
foci of high grade changes, such as necrosis, 
focal loss of papillary-type nuclei, and foci 
with overall aberrant morphology (Rivera 
et al., 2010a,b). Widely invasive follicular 
or Hürthle cell carcinoma may have asso-
ciated foci showing necrosis or increased 
mitoses, and by their nature, they are often 
associated with the STI growth pattern. 
Likely, this is why so many of the subse-
quently studied tumors post-Turin have 
RAS mutations (Ricarte-Filho et al., 2009; 
Volante et al., 2009; Asioli et al., 2010). This 
tumor is not entirely poorly differentiated, 
as you can see a more well-differentiated 
component to it, but drawing a definitive 
diagnostic line between FTC and PDTC 
remains challenging. The truth is that we 
call these tumors many things and often 
diagnose them descriptively, presenting 
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